Copyright © 2005 American Medical Association. All rights reserved. From: Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaMeta-analysis of Randomized Placebo-Controlled Trials JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934 Figure Legend: RCT indicates randomized controlled trial. Date of download: 10/21/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaMeta-analysis of Randomized Placebo-Controlled Trials JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934 Figure Legend: CI indicates confidence interval; OR, odds ratio. *Unique identificationcode which identifies the study or the collection of posters, abstracts, unpublishedmanuscripts, or published trials of the study drug. The total number of placebopatients is 1757 and deaths, 40. The trial HGGU placebo group is used forboth risperidone and olanzapine comparisons. Date of download: 10/21/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaMeta-analysis of Randomized Placebo-Controlled Trials JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934 Figure Legend: CI indicates confidence interval; OR, odds ratio.*Unique identificationcode, which identifies the study or the collection of posters, abstracts,unpublished manuscripts, or published trials of the study drug. The totalnumber of placebo patients is 1757 and dropouts, 551. The trial HGGU placebogroup is used for both risperidone and olanzapine comparisons. Date of download: 10/21/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaMeta-analysis of Randomized Placebo-Controlled Trials JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934 Figure Legend: Total population is patient-years exposure to treatment (drug) or placebo.CI indicates confidence interval; RR, relative risk. Exposure time to treatmentfor 4 risperidone and 3 olanzapine trials was obtained from data presentedby the US Food and Drug Administration. Exposuretime for 1 risperidone trial, 2 olanzapinetrials, and 1 quetiapine trial was estimated from sample sizes, trial lengths, anddropout rates. Exposure time for aripiprazole was calculated from sample sizesand incidence data provided in a letter from Bristol-Myers Squibb (February10, 2005), and for 2 quetiapine trials fromdata provided in Schneider et al. The totalnumber of placebo deaths is 40 and placebo exposure is 303 patient-years (seefootnote to Figure 2). Date of download: 10/21/2017 Copyright © 2005 American Medical Association. All rights reserved.